March 15, 2012 12:13 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Stifel Nicolaus raises its rating on Affymax (NASDAQ: AFFY) to Buy from Hold and establishes a $19 price target on shares as it expects Peginesatide approval on March 27, 2012.Stifel Nicolaus says, "Affymax is preparing to launch lead drug Peginesatide into the U.S. dialysis market in 2Q. An FDA advisory panel voted almost unanimously for approval in December; we expect marketing approval on or before the March 27 PDUFA date. We expect Peginesatide will be a disruptive force in the market for erythropoietin stimulating agents. Amgen has had monopoly pricing power in this market for over twenty years; Peginesatide offers a long-acting (once/month) product, which we expect will be competitively priced in comparison to Amgen's Epogen."AFFY closed at $11.22 a share on Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.